CA3117682A1 - Formulations containing deuterated domperidone - Google Patents
Formulations containing deuterated domperidone Download PDFInfo
- Publication number
- CA3117682A1 CA3117682A1 CA3117682A CA3117682A CA3117682A1 CA 3117682 A1 CA3117682 A1 CA 3117682A1 CA 3117682 A CA3117682 A CA 3117682A CA 3117682 A CA3117682 A CA 3117682A CA 3117682 A1 CA3117682 A1 CA 3117682A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- domperidone
- pharmaceutical formulation
- gastroparesis
- ethylene oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750491P | 2018-10-25 | 2018-10-25 | |
| US62/750,491 | 2018-10-25 | ||
| PCT/US2019/058033 WO2020086947A1 (en) | 2018-10-25 | 2019-10-25 | Formulations containing deuterated domperidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117682A1 true CA3117682A1 (en) | 2020-04-30 |
Family
ID=68582416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117682A Pending CA3117682A1 (en) | 2018-10-25 | 2019-10-25 | Formulations containing deuterated domperidone |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12514852B2 (https=) |
| EP (1) | EP3668510B1 (https=) |
| JP (2) | JP7583728B2 (https=) |
| KR (3) | KR20240068762A (https=) |
| CN (1) | CN113164463B (https=) |
| AU (1) | AU2019366993B2 (https=) |
| CA (1) | CA3117682A1 (https=) |
| ES (1) | ES2852623T3 (https=) |
| IL (1) | IL282575B (https=) |
| SG (1) | SG11202103284QA (https=) |
| WO (1) | WO2020086947A1 (https=) |
| ZA (1) | ZA202102115B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136617A1 (en) * | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
| KR20240068762A (ko) | 2018-10-25 | 2024-05-17 | 신돔 파마, 인크. | 중수소화 돔페리돈을 함유하는 제제 |
| EP4525868A1 (en) * | 2022-04-20 | 2025-03-26 | CinDome Pharma, Inc. | Deuterated domperidone for treating gastroparesis |
| CN120813355A (zh) * | 2023-03-23 | 2025-10-17 | 辛多美制药有限公司 | 用于治疗糖尿病性胃轻瘫的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9702392D0 (en) | 1997-02-06 | 1997-03-26 | Boots Co Plc | Therapeutic agents |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US20050220825A1 (en) | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
| CN1686128A (zh) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | 多潘立酮滴丸及其制备方法 |
| AU2008245580A1 (en) | 2007-04-26 | 2008-11-06 | Craig A. Aronchick | Compositions and methods for transmucosal delivery of domperidone |
| CN102125528A (zh) | 2010-01-12 | 2011-07-20 | 上海中邦斯瑞生物药业技术有限公司 | 多潘立酮口崩片 |
| DE102010015143A1 (de) * | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| WO2017136617A1 (en) * | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
| KR20240068762A (ko) | 2018-10-25 | 2024-05-17 | 신돔 파마, 인크. | 중수소화 돔페리돈을 함유하는 제제 |
| WO2020086950A1 (en) | 2018-10-25 | 2020-04-30 | Cindome Pharma, Inc. | Formulations containing domperidone |
-
2019
- 2019-10-25 KR KR1020247014648A patent/KR20240068762A/ko active Pending
- 2019-10-25 EP EP19804996.7A patent/EP3668510B1/en active Active
- 2019-10-25 JP JP2021547550A patent/JP7583728B2/ja active Active
- 2019-10-25 KR KR1020217015511A patent/KR20210080495A/ko not_active Ceased
- 2019-10-25 CA CA3117682A patent/CA3117682A1/en active Pending
- 2019-10-25 AU AU2019366993A patent/AU2019366993B2/en active Active
- 2019-10-25 CN CN201980069226.8A patent/CN113164463B/zh active Active
- 2019-10-25 WO PCT/US2019/058033 patent/WO2020086947A1/en not_active Ceased
- 2019-10-25 US US17/287,571 patent/US12514852B2/en active Active
- 2019-10-25 KR KR1020237041657A patent/KR102667995B1/ko active Active
- 2019-10-25 SG SG11202103284QA patent/SG11202103284QA/en unknown
- 2019-10-25 ES ES19804996T patent/ES2852623T3/es active Active
-
2021
- 2021-03-29 ZA ZA2021/02115A patent/ZA202102115B/en unknown
- 2021-04-22 IL IL282575A patent/IL282575B/en unknown
-
2022
- 2022-12-09 JP JP2022196699A patent/JP7652751B2/ja active Active
-
2025
- 2025-12-03 US US19/407,389 patent/US20260083717A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210080495A (ko) | 2021-06-30 |
| JP7652751B2 (ja) | 2025-03-27 |
| US12514852B2 (en) | 2026-01-06 |
| CN113164463B (zh) | 2022-09-20 |
| KR102667995B1 (ko) | 2024-05-23 |
| KR20240068762A (ko) | 2024-05-17 |
| NZ774559A (en) | 2025-02-28 |
| JP7583728B2 (ja) | 2024-11-14 |
| IL282575B (en) | 2022-05-01 |
| EP3668510A1 (en) | 2020-06-24 |
| CN113164463A (zh) | 2021-07-23 |
| JP2022512041A (ja) | 2022-02-01 |
| EP3668510B1 (en) | 2021-01-13 |
| WO2020086947A1 (en) | 2020-04-30 |
| US20220110929A1 (en) | 2022-04-14 |
| AU2019366993B2 (en) | 2024-02-15 |
| ZA202102115B (en) | 2023-10-25 |
| ES2852623T3 (es) | 2021-09-14 |
| JP2023036663A (ja) | 2023-03-14 |
| IL282575A (en) | 2021-06-30 |
| US20260083717A1 (en) | 2026-03-26 |
| SG11202103284QA (en) | 2021-05-28 |
| AU2019366993A1 (en) | 2021-05-06 |
| KR20230169456A (ko) | 2023-12-15 |
| BR112021007754A2 (pt) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260083717A1 (en) | Formulations containing deuterated domperidone | |
| US20260042790A1 (en) | Pentaaza macrocyclic ring complexes possessing oral bioavailability | |
| WO2003045357A1 (en) | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof | |
| KR102706357B1 (ko) | 제약 제제 | |
| KR20140016926A (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
| AU2024202861A1 (en) | Formulations containing domperidone | |
| RU2796537C2 (ru) | Составы, содержащие дейтерированный домперидон | |
| HK40033044A (en) | Formulations containing deuterated domperidone | |
| HK40033044B (en) | Formulations containing deuterated domperidone | |
| WO2020053658A2 (en) | Non-aqueous chemotherapeutic solutions for oral dosage | |
| HK40033468B (en) | Formulations containing domperidone | |
| HK40033468A (en) | Formulations containing domperidone | |
| BR112021007754B1 (pt) | Formulações contendo domperidona deuterada e uso das mesmas | |
| BR112021007755B1 (pt) | Formulações contendo domperidona e uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20240925 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241004 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241017 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250109 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250328 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250328 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250328 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260128 |